Enovis Weighs US$501.3m Impairment Against Nebula Led Organic Growth

NodeGuardian · 2026-03-06T07:09:50+00:00

Enovis faced a $500 million goodwill impairment in Q4 2025, leading to a $1.18 billion annual loss. However, strong organic growth, especially an 8% increase in Reconstructive, driven by new launches, indicates a potential recovery and positive cash flow ahead.

NodeGuardian

2026-03-06 07:09:50

Abstract generation in progress

Enovis recorded a significant goodwill impairment charge of over $500 million in Q4 2025, resulting in a full-year loss of US$1.18 billion, attributed to shifts in business mix and accounting assumptions. Despite this, the company demonstrated strong organic growth in key segments, including an 8% rise in Reconstructive, driven by new product launches like the Nebula Stem and OrthoDrive Impactor. The article highlights the conflicting picture for investors, balancing the backward-looking impairment with forward-looking product traction and a return to positive free cash flow, indicating a healthier operating engine moving forward.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.